Tag:

Pfizer

Latest Headlines

Latest Headlines

It's official: The Pfizer-AstraZeneca deal talk can resume

Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.

Looking for a Xalkori boost, Pfizer adds targeted med to Merck IO pact

Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.

Pfizer and Merck extend heavyweight immuno-oncology pact to lung cancer

Merck and Pfizer have struck a deal to add the immuno-oncology superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.

Pfizer-AstraZeneca sequel could hit theaters next week

Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.

Pfizer, BMS pad bright Q2 with new FDA nod for Eliquis

Pfizer and Bristol-Myers Squibb's Eliquis has been lagging since launch time, trailing behind predecessors Pradaxa and Xarelto. But lately, the drugmakers' efforts have been paying off when it comes to market share, and a new indication may help keep the ball rolling.

Lilly's strong results for psoriasis drug come on heels of data from Novartis

Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.

What keeps C-suite execs up at night? Brands, launches, and cutting costs

Look under a pharma executive's bed, and you'll find monsters. What do those monsters look like, though? Accenture talked to C-suite executives at the world's biggest drugmakers and found that some of yesteryear's scary beings have moved on, leaving others to take front and center.

Pfizer recalls nearly 94,000 vials of Depo-Medrol

Pfizer is recalling two lots of its 40 mg/ mL, 1 mL single-dose vials  of its anti inflammatory product Depo-Medrol.

Pfizer eyes Actavis in backup plan to another AstraZeneca bid

Pfizer may not get a great shot at buying AstraZeneca this fall--but it's preparing to give it a try. Meanwhile, Bloomberg reports, the U.S.-based drug giant is looking at Actavis, the generics maker with a new home address in Ireland, among other targets.

Big Pharma stands back as little guys work on plant-based drugs and manufacturing

When it comes to manufacturing, Big Pharma prefers traditional plants to living plants. While drugs manufactured from plants like tobacco have been in the news because several makers of Ebola drug candidates are using the process, the method has not been embraced by any of the major players.